DCA Study

Pulmonary arterial hypertension is an uncommon disease with few treatment options. It results from structural changes in the blood vessels of the lung, and leads to increased pressure on the right side of the heart and premature death from heart failure. A characteristic of dividing cells is that they need more glucose. Dicloroacetate (DCA) changes the way cells handle glucose and works to restore a normal metabolism. This study, funded by the MRC, is investigating a safe dose of DCA that might be given to patients with pulmonary hypertension to treat their disease. The study measures the effect of DCA on heart function, and uses the latest imaging technologies (PET and MRI) to adjust the dose of DCA.

Study number: 219

PI: Professor Martin Wilkins

DCA Study